Plexin B2 Gene Expression and Polymorphisms in Psoriasis : Relation to Narrow Band Ultraviolet B , Acitretin and Combined Therapy

• Status: Active, not recruiting
• Trial end date: 2023-08-15
• Target enrollment: 0
• Participant gender: All

Summary

Patients will be randomly assigned (1:1:1 ) either to ; NB-UVB photo-therapy alone , Acitretin therapy alone or NB-UVB photo-therapy combined with Acitretin therapy randomization will be done by closed envelopes . investigator will be blinded to study drug assignment , while patients and data interpreter will not be masked to study drug assignment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: South Valley University
• Treatments: Acitretin

Criteria

Inclusion Criteria:

• Patients of both sexes. Diagnosed clinically with moderate to severe Psoriasis Vulgaris.

• patients able to swallow tablet and receive Narrow band Ultraviolet B phototherapy without any contraindication

Exclusion Criteria:

Pregnancy , lactation & women intent to become pregnant within 3 year after discontinuation of acitretin Patients with Hyperlipidemia Patients with mental problems and depression Patients with a history of malignancies, renal & liver diseases. Patients with a history of any inflammatory diseases as atopic dermatitis , asthma ulcerative colitis ) and Crohn's disease Patients received NB-UVB phototherapy in the last 6 months. Patients treated with methotrexate or biologic agents and any systemic treatment of psoriasis.